Self-reported Measures May Accurately Identify Cancer-Related Fatigue
the Cancer Therapy Advisor take:
Brief screening indices derived from self-report fatigue measures can accurately identify cancer-related fatigue (CRF) in patients with breast cancer and survivors, according to an article published online in the journal Psycho-Oncology.
Participants in the study included patients with breast cancer (n=385) who completed a fatigue diagnostic interview and various self-report fatigue measures at three different times: after initial adjuvant therapy (post-treatment [post-Tx] 1 assessment), after completing radiotherapy for women receiving chemotherapy + radiotherapy (post-Tx 2 assessment), and 6 months after completing all adjuvant therapy (6-month post-Tx assessment).
Results showed out of the 385 women, 104 (27%) met CRF criteria after receiving initial adjuvant therapy.
For all indices, the area of the curve was determined to exceed 0.80, sensitivity exceeded 0.80, and specificity exceeded 0.57.
Furthermore, all the indices, except for the index based on SF-36, accurately identified CRF cases at both the post-Tx 2 and 6-month post-Tx assessments.
The authors noted the “most severity” and “work interference” items on the two-item composite index based on the Fatigue Symptom Inventory had the best performance.
Brief screening indices derived from self-report fatigue measures can accurately identify cancer-related fatigue in breast cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Opinion: Understanding the FDA's Take on Cannabidiol
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Polymorphism in HSD3B1 as a Potential Prognostic Biomarker in Prostate Cancer
- Opioid Use and Cancer
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk